- Conditions
- Atrial Fibrillation, Thromboembolism
- Interventions
- Edoxaban (DU-176b), warfarin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 22
- States / cities
- Huntsville, Alabama • Anaheim, California • Beverly Hills, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1825–1848
of 13,797
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia, Hair Loss
- Interventions
- VDPHL01 QD, Placebo, VDPHL01 BID
- Drug
- Lead sponsor
- Veradermics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 65 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- CagriSema
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Fountain Valley, California • Glendora, California + 37 more
- Conditions
- Pruritus
- Interventions
- 5 mg Serlopitant Tablets, Matching Placebo Tablets
- Drug
- Lead sponsor
- Vyne Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 41
- States / cities
- Hot Springs, Arkansas • Bakersfield, California • Fremont, California + 36 more
- Conditions
- Spinal Muscular Atrophy (SMA)
- Interventions
- Not listed
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 15
- States / cities
- Davis, California • Los Angeles, California • Aurora, Colorado + 12 more
- Conditions
- Drug-drug Interaction
- Interventions
- Omeprazole 40 MG, Famotidine 40 mg, Telotristat ethyl 250 mg
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Covid19
- Interventions
- VIR-7831 (sotrovimab), Placebo
- Biological · Drug
- Lead sponsor
- Vir Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,057 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 63
- States / cities
- Anniston, Alabama • Cullman, Alabama • Mesa, Arizona + 49 more
- Conditions
- Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
- Interventions
- Atezolizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Quality-of-Life Assessment
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 712 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1026
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 683 more
- Conditions
- Corneal Edema Secondary to Corneal Endothelial Dystrophy
- Interventions
- DSAEK, Anterior Segment Optical Coherence Topography (OCT), Best Spectacle Corrected Visual Acuity (BSCVA)
- Procedure · Diagnostic Test
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hereditary Angioedema
- Interventions
- C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline)
- Biological · Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • San Diego, California • Walnut Creek, California + 13 more
- Conditions
- Relapsed Refractory Multiple Myeloma
- Interventions
- Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide, Erdafitinib, dexamethasone, ixazomib, pomalidomide, Venetoclax, dexamethasone, ixazomib, pomalidomide, Daratumumab, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Selinexor, dexamethasone, ixazomib, pomalidomide
- Drug
- Lead sponsor
- Multiple Myeloma Research Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Duarte, California • Atlanta, Georgia + 10 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil Palmitil, Placebo
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more
- Conditions
- Dry Eye Syndrome
- Interventions
- Tetracycline: Doxycycline analog
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 88 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Interventions
- Tirzepatide, Placebo
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 938 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more
- Conditions
- Bipolar I Disorder
- Interventions
- Lurasidone
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 25
- States / cities
- Dothan, Alabama • Glendale, California • Los Angeles, California + 22 more
- Conditions
- Chronic Low Back Pain
- Interventions
- Hydrocodone bitartrate q24h film-coated tablets, Placebo to match hydrocodone bitartrate q24h tablets
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 905 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 102
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 83 more
- Conditions
- Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
- Interventions
- Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Patient Observation
- Drug · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 932
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 639 more
- Conditions
- Osteoarthritis, Knee, Pain
- Interventions
- CGS-200-1, CGS-200-5, CGS-200 Vehicle
- Drug
- Lead sponsor
- Propella Therapeutics
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 6
- States / cities
- Clearwater, Florida • Tampa, Florida • Cincinnati, Ohio + 2 more
- Conditions
- Knee Osteoarthritis
- Interventions
- Lorecivivint, Placebo
- Drug
- Lead sponsor
- Biosplice Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • Cerritos, California • La Mesa, California + 35 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, cisplatin, cytarabine, methylprednisolone, pixantrone dimaleate, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Theradex
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 28
- States / cities
- Tucson, Arizona • Duarte, California • Los Angeles, California + 23 more
- Conditions
- Psoriatic Arthritis (PsA)
- Interventions
- Deucravacitinib, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Lovastatin ™, placebo
- Drug · Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 8 Years to 15 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
- Interventions
- Cisplatin, Panitumumab, Docetaxel
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 82
- States / cities
- Tucson, Arizona • Jonesboro, Arkansas • Duarte, California + 67 more
- Conditions
- Thoracic Tumors, Non-small Cell Lung Cancer
- Interventions
- Anvumetostat, Carboplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Sotorasib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Bakersfield, California • Duarte, California • Los Angeles, California + 20 more